Acelyrin (SLRN) Competitors

Design Therapeutics presently has a consensus target price of $16.50, indicating a potential upside of 13.40%. Given Design Therapeutics' stronger consensus rating and higher possible upside, research analysts clearly believe Design Therapeutics is more favorable than Acelyrin.

In the previous week, Design Therapeutics had 8 more articles in the media than Acelyrin. MarketBeat recorded 8 mentions for Design Therapeutics and 0 mentions for Acelyrin. Design Therapeutics' average media sentiment score of 0.42 beat Acelyrin's score of 0.00 indicating that Design Therapeutics is being referred to more favorably in the media.

Design Therapeutics' return on equity of -33.07% beat Acelyrin's return on equity.

56.6% of Design Therapeutics shares are held by institutional investors. Comparatively, 87.3% of Acelyrin shares are held by institutional investors. 23.5% of Design Therapeutics shares are held by company insiders. Comparatively, 13.6% of Acelyrin shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Design Therapeutics is trading at a lower price-to-earnings ratio than Acelyrin, indicating that it is currently the more affordable of the two stocks.

Design Therapeutics has a beta of 1.73, meaning that its stock price is 73% more volatile than the S&P 500. Comparatively, Acelyrin has a beta of 1.07, meaning that its stock price is 7% more volatile than the S&P 500.

Janux Therapeutics has a beta of 2.58, suggesting that its stock price is 158% more volatile than the S&P 500. Comparatively, Acelyrin has a beta of 1.07, suggesting that its stock price is 7% more volatile than the S&P 500.

In the previous week, Janux Therapeutics had 5 more articles in the media than Acelyrin. MarketBeat recorded 5 mentions for Janux Therapeutics and 0 mentions for Acelyrin. Janux Therapeutics' average media sentiment score of 1.01 beat Acelyrin's score of 0.00 indicating that Janux Therapeutics is being referred to more favorably in the media.

Janux Therapeutics currently has a consensus target price of $49.75, indicating a potential upside of 240.29%. Given Janux Therapeutics' stronger consensus rating and higher probable upside, research analysts clearly believe Janux Therapeutics is more favorable than Acelyrin.

75.4% of Janux Therapeutics shares are owned by institutional investors. Comparatively, 87.3% of Acelyrin shares are owned by institutional investors. 8.1% of Janux Therapeutics shares are owned by insiders. Comparatively, 13.6% of Acelyrin shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Janux Therapeutics' return on equity of -12.61% beat Acelyrin's return on equity.

Janux Therapeutics has higher revenue and earnings than Acelyrin. Janux Therapeutics is trading at a lower price-to-earnings ratio than Acelyrin, indicating that it is currently the more affordable of the two stocks.

Acelyrin has a beta of 1.07, meaning that its stock price is 7% more volatile than the S&P 500. Comparatively, Theravance Biopharma has a beta of 0.19, meaning that its stock price is 81% less volatile than the S&P 500.

In the previous week, Theravance Biopharma had 2 more articles in the media than Acelyrin. MarketBeat recorded 2 mentions for Theravance Biopharma and 0 mentions for Acelyrin. Acelyrin's average media sentiment score of 0.00 beat Theravance Biopharma's score of -0.09 indicating that Acelyrin is being referred to more favorably in the media.

87.3% of Acelyrin shares are owned by institutional investors. Comparatively, 99.1% of Theravance Biopharma shares are owned by institutional investors. 13.6% of Acelyrin shares are owned by insiders. Comparatively, 6.9% of Theravance Biopharma shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Theravance Biopharma has higher revenue and earnings than Acelyrin. Acelyrin is trading at a lower price-to-earnings ratio than Theravance Biopharma, indicating that it is currently the more affordable of the two stocks.

Theravance Biopharma has a net margin of 98.54% compared to Acelyrin's net margin of 0.00%. Theravance Biopharma's return on equity of 16.76% beat Acelyrin's return on equity.

Theravance Biopharma has a consensus target price of $21.83, suggesting a potential upside of 28.89%. Given Theravance Biopharma's stronger consensus rating and higher probable upside, analysts plainly believe Theravance Biopharma is more favorable than Acelyrin.

Arbutus Biopharma has a beta of 0.62, suggesting that its stock price is 38% less volatile than the S&P 500. Comparatively, Acelyrin has a beta of 1.07, suggesting that its stock price is 7% more volatile than the S&P 500.

In the previous week, Arbutus Biopharma had 2 more articles in the media than Acelyrin. MarketBeat recorded 2 mentions for Arbutus Biopharma and 0 mentions for Acelyrin. Arbutus Biopharma's average media sentiment score of 1.27 beat Acelyrin's score of 0.00 indicating that Arbutus Biopharma is being referred to more favorably in the media.

43.8% of Arbutus Biopharma shares are held by institutional investors. Comparatively, 87.3% of Acelyrin shares are held by institutional investors. 19.9% of Arbutus Biopharma shares are held by company insiders. Comparatively, 13.6% of Acelyrin shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Arbutus Biopharma has higher revenue and earnings than Acelyrin. Arbutus Biopharma is trading at a lower price-to-earnings ratio than Acelyrin, indicating that it is currently the more affordable of the two stocks.

Acelyrin has a net margin of 0.00% compared to Arbutus Biopharma's net margin of -237.88%. Arbutus Biopharma's return on equity of -42.39% beat Acelyrin's return on equity.

Arbutus Biopharma currently has a consensus target price of $5.00, suggesting a potential upside of 13.12%. Given Arbutus Biopharma's stronger consensus rating and higher possible upside, analysts plainly believe Arbutus Biopharma is more favorable than Acelyrin.